Gilead pays $1.28B upfront to China's PepStar Therapeutics for oral IL-23 inhibitor HCXT-2001, targeting IBD and psoriasis, ...
Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...
Roche touts 88% Phase 3 success rate as it culls afimkibart’s AD trial and seven early assets ahead of giredestrant launch.
Roche’s Teresa Graham says patients are clamoring for breast cancer pill giredestrant as two US approval decisions near.
Arbutus' AB-101 hold lifted; GSK drops HBV drug; Ultomiris approved for IgAN; Biohaven resubmits SCA app; Arcus raises $250M; ...
Sanofi breaks ground on a Frankfurt insulin plant, FDA warns Baxter over cephalosporin contamination, and radiopharma players ...
AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response rates after 16 weeks by a statistically significant ...
FDA weighs evidence standards for AI medical devices like prescription bots. AMA opposes upfront uncertainty; ATA Action supports post-market monitoring. UpDoc, AMA, and others back risk-based ...
Redesign Health merges with Sheba Medical Center’s ARC Global in a roughly $2B deal and plans to acquire advisory firm AVIA.
Rezera (formerly NodThera) filed for Nasdaq IPO as $RZRA, targeting Phase 3 for PAD in 2027 with NLRP3 inhibitor ruvonoflast. Novo Holdings and Blue Owl Capital each own 24%.
Roivant's brepocitinib (Lisraya) succeeded in two non-infectious uveitis trials, with plans to file for approval in H1 2027.
Pharma braces for a tougher Treasury scrutiny of China deals as draft outbound investment rules are expected Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results